<DOC>
	<DOCNO>NCT01475058</DOCNO>
	<brief_summary>This phase I/II trial study safety toxicity post-transplant treatment donor T cell engineer express chimeric antigen receptor ( CAR ) target CD19 patient match related allogeneic hematopoietic stem cell transplant CD19+ B cell malignancy .</brief_summary>
	<brief_title>CD19 CAR T Cells B Cell Malignancies After Allogeneic Transplant</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To assess safety feasibility pre-emptive adoptive T cell therapy use ex vivo expand cytomegalovirus ( CMV ) - Epstein-Barr virus ( EBV ) -specific T cell derive donor CD62L+ central memory ( TCM ) cell genetically modify express CD19-specific chimeric antigen receptor ( CAR ) patient complete remission human leukocyte antigen ( HLA ) -matched related donor hematopoietic stem cell transplantation ( HCT ) CD19+ B cell malignancy high risk post-HCT relapse . ( Cohort A ) II . To assess safety feasibility adoptive T cell therapy use ex vivo expand CMV- EBV-specific T cell derive donor CD62L+ TCM cell genetically modify express CD19-specific CAR patient persistent , progressive relapse disease HLA-matched related donor HCT CD19+ B cell malignancy . ( Cohort B ) SECONDARY OBJECTIVES : I . To determine duration vivo persistence adoptively transfer bi-specific CD8+ T cell , phenotype persist T cell . II . To determine adoptively transfer bi-specific CD8+ T cell traffic bone marrow function vivo . III . To determine adoptively transfer bi-specific CD8+ T cell proliferate allogeneic HCT recipient reactivate CMV EBV . IV . To determine adoptive transfer bi-specific CD8+ T cell eliminate CD19+ tumor cell subset patient measurable tumor burden prior T cell transfer . OUTLINE : At least 30 day HCT , patient receive one intravenous ( IV ) infusion CMV/CD19 EBV/CD19 bi-specific CD8+ T cell . After completion study treatment , patient follow periodically 15 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<criteria>Patients CD19+ B cell malignancy persistent , relapse progressive disease hematopoietic stem cell transplant human leukocyte antigen ( HLA ) match related donor OR patient CD19+ B cell malignancy plan hematopoietic stem cell transplant HLAmatched relate donor risk relapse HCT define one diseasespecific criterion list : Philadelphia chromosome negative acute lymphoblastic leukemia : Beyond first complete remission ( CR ) time pretransplant evaluation Required &gt; 1 cycle induction chemotherapy achieve CR First morphologic CR evidence minimal residual disease flow cytometry , conventional cytogenetics , fluorescence situ hybridization ( FISH ) polymerase chain reaction ( PCR ) First CR poor risk cytogenetics ( ( 4:11 ) , ( 8 ; 14 ) , hypodiploidy , near triploidy &gt; 5 cytogenetic abnormality ) diagnosis Planned reduce intensity condition nonmyeloablative transplant Philadelphia positive acute lymphoblastic leukemia Not CR time pretransplant evaluation In CR follow feature : Intolerant unwilling use TKI HCT Current previous detection cytogenetic abnormality addition ( 9 ; 22 ) conventional karyotyping , FISH molecular method Chronic lymphocytic leukemia , low grade B cell lymphoma : Failed ineligible prior immunochemotherapy include purine analog antiCD20 monoclonal antibody AND lymph node &gt; = 5 cm time pretransplant evaluation Mantle cell lymphoma : Failed ineligible autologous transplant AND lymph node &gt; = 2 cm time pretransplant evaluation Diffuse large B cell lymphoma , large B cell transformation indolent lymphoma aggressive B cell lymphoma Failed ineligible autologous transplant AND CR time pretransplant evaluation Confirmation tumor diagnosis expression CD19 review University Washington Medical Center ( UWMC ) Seattle Cancer Care Alliance ( SCCA ) pathology service The patient sign informed consent form study DONOR : Genotypic phenotypic HLAidentical family member DONOR : Express one follow combination viral serostatus HLA allele : CMV seropositive HLAA*0101 positive CMV seropositive HLAA*0201 positive CMV seropositive HLAB*0702 positive CMV seropositive HLAB*0801 positive EBV seropositive HLAA*0201 positive EBV seropositive HLAB*0801 positive DONOR : Hematocrit &gt; = 35 % enrollment DONOR : Age &gt; = 18 year DONOR : The donor sign informed consent form study Known central nervous system ( CNS ) tumor ( CNS2 CNS3 ) refractory intrathecal chemotherapy and/or craniospinal radiation ; patient history CNS disease effectively treat CNS1 low evidence disease eligible Human immunodeficiency virus ( HIV ) seropositive Significant medical psychological condition would make unsuitable candidate T cell therapy Fertile patient unwilling use contraception 12 month protocol enrollment Pregnant breastfeed DONOR : GCSF administer within one month prior blood draw T cell collection DONOR : Unable reason provide 400 ml blood draw DONOR : Inadequate peripheral vein blood collection DONOR : HIV1 , HIV2 , human Tlymphotropic virus ( HTLV ) 1 HTLV2 seropositive DONOR : Active hepatitis B hepatitis C virus infection DONOR : Positive serologic test syphilis DONOR : Aberrant CD45RA isoform expression T cell DONOR : Systolic blood pressure ( BP ) &lt; 80 &gt; 200 DONOR : Heart rate &lt; 50 &gt; 120 , consider due cardiac disease DONOR : Oxygen ( O2 ) saturation &lt; 88 % room air DONOR : Serum creatinine ( Cr ) &gt; 3.0 DONOR : Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 4 x upper limit normal DONOR : Unable provide inform consent participate DONOR : Significant medical condition ( e.g . immunosuppressive therapy ) would make unsuitable T cell donor DONOR : Pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>